Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyclezyme ABXSAT:CYCLE +4.59%6 Debt-to-Equity is 0.04 as of Jun. 2026, which is 43% below its 10-year median of 0.07. GuruFocus rates XSAT:CYCLE with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,420 Chemicals companies, Cyclezyme AB ranks better than 88.87% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cyclezyme AB's Debt-to-Equity or its related term are showing as below:
XSAT:CYCLE'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.07 Max: 0.1
Current: 0.04
During the past 6 years, the highest Debt-to-Equity Ratio of Cyclezyme AB was 0.10. The lowest was 0.01. And the median was 0.07.
XSAT:CYCLE's Debt-to-Equity is ranked better than 88.87% of 1420
companies
in the Chemicals industry
Industry Median: 0.37
vs XSAT:CYCLE: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cyclezyme AB Debt-to-Equity Related Terms
Cyclezyme AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cyclezyme AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CYCLE vs LIN, SHW, ECL: Debt-to-Equity Comparison
For the Specialty Chemicals subindustry, Cyclezyme AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclezyme AB Debt-to-Equity vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Cyclezyme AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cyclezyme AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclezyme AB (XSAT:CYCLE) has a Debt-to-Equity of 0.04 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cyclezyme AB and its competitors. This is 43% below median its historical median of 0.07. Over the past decade, Cyclezyme AB's Debt-to-Equity has ranged from 0.01 to 0.10. According to the industry distribution chart, Cyclezyme AB ranks #158 out of 1420 companies in the Chemicals industry, placing it in the top 11.1%.
Is Cyclezyme AB's Debt-to-Equity too high?
Cyclezyme AB's current Debt-to-Equity of 0.04 is 43% below median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.10. The Chemicals industry median Debt-to-Equity is 0.37. Cyclezyme AB's value of 0.04 is 89.2% below this industry median. Based on the distribution chart, Cyclezyme AB ranks #158 out of 1420 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Cyclezyme AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cyclezyme AB's Debt-to-Equity compare to LIN and SHW?
According to the Chemicals industry distribution chart, Cyclezyme AB ranks #158 out of 1420 companies for Debt-to-Equity. This places Cyclezyme AB in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.37. Cyclezyme AB's value of 0.04 is 89.2% below this benchmark. Historically, Cyclezyme AB's own Debt-to-Equity has ranged from 0.01 to 0.10 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.37, Cyclezyme AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Chemicals company?
The median Debt-to-Equity among Chemicals companies is 0.37, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyclezyme AB's current Debt-to-Equity of 0.04 is 89.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cyclezyme AB and its competitors. For the Chemicals industry, the median Debt-to-Equity is 0.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclezyme AB's current Debt-to-Equity is 0.04, which is 43% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclezyme AB stock overvalued right now?
Cyclezyme AB (XSAT:CYCLE) has a current Debt-to-Equity of 0.04. The current Debt-to-Equity is 0.04, which is 43% below median its 10-year median of 0.07 and 89.2% below the Chemicals industry median of 0.37. Cyclezyme AB's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cyclezyme AB (XSAT:CYCLE), the current Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cyclezyme AB is a Sweden-based company that has developed an enzymatic platform focused on producing enzymes for green biochemical processes. This platform utilizes biotechnological methods to identify and improve enzymes capable of converting e.g. PET-based plastic materials for new building blocks. The company enables careful experiments and analyses of the behavior of different enzymes in the breakdown of e.g. PET material. The company refines its enzymes and also optimizes the processes for plastic recycling by combining experimental data with data analysis.
6GF Score
Get the complete analysis for XSAT:CYCLE
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CYCLE has been successfully added to your 
